Aligos Therapeutics Inc. (ALGS), a clinical-stage biopharmaceutical company, on Wednesday presented positive data from ten presentations evaluating Pevifoscorvir sodium in treating chronic hepatitis B and other ongoing studies at the European Association for the Study of the Liver (EASL) congress, 2026.